Study on Efficacy, Safety and Durability of the UniLine Prosthesis in the Treatment of Aortic and Mitral Valve Disease
NCT ID: NCT05895487
Last Updated: 2024-09-26
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
2000 participants
Study Classification
OBSERVATIONAL
Study Start Date
2022-11-01
Study Completion Date
2026-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Acquired heart diseases continue to remain one of the most common causes of cardiac mortality and morbidity. In the Russian Federation, open surgery treatment of acquired valvular heart diseases (AVHD) is performed in more than 40 regions by specialists from 92 healthcare organizations.
Treating aortic or mitral valve disease using the "UniLine" biological prosthesis is expected to improve survival rates. Supposedly, in vivo the "UniLine" biological prosthesis will show optimal hemodynamic characteristics and high resistance to structural valve degeneration and infectious damage, thus lowering the risk of dysfunction. Moreover, the risk of repeated intervention due to dysfunction of the "UniLine" bioprosthesis should not exceed the risk of the primary implantation. Supposedly, in the case of dysfunction of "UniLine" bioprosthesis it would be possible to perform repeated replacement using valve-in-valve technique.
The aim of the study is to assess the effectiveness, safety, durability of the "UniLine" epoxy-treated prosthesis and the long-term outcome of the treatment of isolated mitral and aortic valve diseases using this prosthesis.
In accordance with the objectives and hypothesis, the following data will be analyzed: actuarial and linear survival rates (general and cardiac), non-lethal prosthesis-associated complications, prosthetic dysfunction and repeated interventions.
Moreover, in vivo hemodynamic parameters of the prosthesis will be assessed: the area of the effective opening surface, peak and mean gradient of pressure and blood flow velocity.
The study will be conducted at the Research Institute of Complex Issues of Cardiovascular Diseases. Study protocol received sponsorship approval and approval by Local Ethics Committee of the Research Institute and Research Coordinating Committee. The study will enroll patients who underwent isolated mitral or aortic valve replacement; transthoracic echocardiography will be conducted in all patients available for in-person visit.
Treating aortic or mitral valve disease using the "UniLine" biological prosthesis is expected to improve survival rates. Supposedly, in vivo the "UniLine" biological prosthesis will show optimal hemodynamic characteristics and high resistance to structural valve degeneration and infectious damage, thus lowering the risk of dysfunction. Moreover, the risk of repeated intervention due to dysfunction of the "UniLine" bioprosthesis should not exceed the risk of the primary implantation. Supposedly, in the case of dysfunction of "UniLine" bioprosthesis it would be possible to perform repeated replacement using valve-in-valve technique.
The aim of the study is to assess the effectiveness, safety, durability of the "UniLine" epoxy-treated prosthesis and the long-term outcome of the treatment of isolated mitral and aortic valve diseases using this prosthesis.
In accordance with the objectives and hypothesis, the following data will be analyzed: actuarial and linear survival rates (general and cardiac), non-lethal prosthesis-associated complications, prosthetic dysfunction and repeated interventions.
Moreover, in vivo hemodynamic parameters of the prosthesis will be assessed: the area of the effective opening surface, peak and mean gradient of pressure and blood flow velocity.
The study will be conducted at the Research Institute of Complex Issues of Cardiovascular Diseases. Study protocol received sponsorship approval and approval by Local Ethics Committee of the Research Institute and Research Coordinating Committee. The study will enroll patients who underwent isolated mitral or aortic valve replacement; transthoracic echocardiography will be conducted in all patients available for in-person visit.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Study on the Use of "UniLine" Bioprosthesis in the Treatment of Isolated Aortic and Mitral Valve Diseases
NCT06025149
Aortic Valve Disease
Mitral Valve Disease
RECRUITING
Early Safety and Clinical Efficacy of Mitral Allograft in Tricuspid Surgery
NCT06196684
Allografts
Tricuspid Valve Insufficiency
ACTIVE_NOT_RECRUITING
Resynchronization Surgery Combined Unified Efficacy
NCT00846001
Ischemic Heart Failure
COMPLETED
PHASE3
Clinical and Fundamental Aspects of Prosthetics and Translocation of Mitral Valve Chordae
NCT03674593
Degenerative Mitral Valve Disease
ACTIVE_NOT_RECRUITING
NA
Surgical Treatment of Ischemic Mitral Regurgitation
NCT01368575
Mitral Valve Insufficiency
UNKNOWN
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Acquired heart diseases continue to remain one of the most common causes of cardiac mortality and morbidity. In Russia, heart valve diseases account for 7 to 25% of all cardiovascular diseases, moreover, they rank third as the cause of heart failure. Prosthetic heart valves commonly used as an effective treatment of acquired valvular heart diseases (AVHD). In the Russian Federation, open surgery treatment of AVHD is performed in more than 40 regions by specialists from 92 healthcare organizations. Surgeries on heart valves, being high-tech care, most effectively prolong the life of patients. Timely treatment of the disease allows 75-95% of patients to return to an active lifestyle and work. The purpose of surgical interventions is to increase life expectancy and to improve the quality of life, which can be achieved via adequate changes in intracardiac hemodynamics and reverse remodeling in the postoperative period.
Bioprosthetic heart valves, unlike most mechanical valves, are characterized by high thromboresistance, optimal (similar to native) hemodynamics parameters and quietness; they improve the quality of life of patients and do not require anticoagulant therapy in the long-term postoperative period. Moreover, bioprosthetic valve dysfunction develops slowly (within a few months or years), meaning that there is time for further examination and preoperative preparation, and a patient's life can be saved.
The "UniLine" bioprosthesis is designed for mitral or aortic valve replacement. This medical device has been used in clinical practice since 2008. Manufacturing of the "UniLine" bioprosthesis involves novel and innovative technologies, including high-precision thickness measurement and laser cutting for the leaflets, which prevents the unfolding of collagen structure along the edge of the cut, and ensures maximum uniformity of the material used, preventing the development of fatigue-induced changes. Unique modeling of leaflets provides complete coaptation. Anticalcification treatment with aminophosphonates contributes to a significant decrease in calcium-binding capacity, which helps to reduce the risk of dysfunction. The absence of synthetic components in the bioprosthesis should reduce the likelihood of endocarditis. Xenopericardium is preserved by using the epoxide compound (diglycidyl ether of ethylene glycol) under low pressure. Each "UniLine" bioprosthesis is subject to mandatory preclinical hydrodynamic assessment in accordance with the National Standards of the Russian Federation (GOST 26997-2003 and GOST 52999-2008). The "UniLine" atrioventricular biological prosthesis is manufactured in standard sizes 26, 28, 30 and 32, the "UniLine" aortic biological prosthesis is manufactured in standard sizes 21, 23, 25.
Treating aortic or mitral valve disease using the "UniLine" biological prosthesis is expected to improve survival rates. Supposedly, in vivo the "UniLine" biological prosthesis will show optimal hemodynamic characteristics and high resistance to structural valve degeneration and infectious damage, thus lowering the risk of dysfunction. Moreover, the risk of repeated intervention due to dysfunction of the "UniLine" bioprosthesis should not exceed the risk of the primary implantation. Supposedly, in the case of dysfunction of "UniLine" bioprosthesis it would be possible to perform repeated replacement using valve-in-valve technique.
The aim of the study is to assess the effectiveness, safety, durability of the "UniLine" epoxy-treated prosthesis and the long-term outcome of the treatment of isolated mitral and aortic valve diseases using this prosthesis.
In accordance with the objectives and hypothesis, the following data will be analyzed: actuarial and linear survival rates (general and cardiac), non-lethal prosthesis-associated complications, prosthetic dysfunction and repeated interventions.
Moreover, in vivo hemodynamic parameters of the prosthesis will be assessed: the area of the effective opening surface, peak and mean gradient of pressure and blood flow velocity.
The study will be conducted at the Research Institute of Complex Issues of Cardiovascular Diseases. Study protocol received sponsorship approval and approval by Ethics Committee of the Research Institute and Research Coordinating Committee. The study will enroll 2000 patients who underwent isolated mitral or aortic valve replacement; transthoracic echocardiography will be conducted in all patients available for in-person visit.
Bioprosthetic heart valves, unlike most mechanical valves, are characterized by high thromboresistance, optimal (similar to native) hemodynamics parameters and quietness; they improve the quality of life of patients and do not require anticoagulant therapy in the long-term postoperative period. Moreover, bioprosthetic valve dysfunction develops slowly (within a few months or years), meaning that there is time for further examination and preoperative preparation, and a patient's life can be saved.
The "UniLine" bioprosthesis is designed for mitral or aortic valve replacement. This medical device has been used in clinical practice since 2008. Manufacturing of the "UniLine" bioprosthesis involves novel and innovative technologies, including high-precision thickness measurement and laser cutting for the leaflets, which prevents the unfolding of collagen structure along the edge of the cut, and ensures maximum uniformity of the material used, preventing the development of fatigue-induced changes. Unique modeling of leaflets provides complete coaptation. Anticalcification treatment with aminophosphonates contributes to a significant decrease in calcium-binding capacity, which helps to reduce the risk of dysfunction. The absence of synthetic components in the bioprosthesis should reduce the likelihood of endocarditis. Xenopericardium is preserved by using the epoxide compound (diglycidyl ether of ethylene glycol) under low pressure. Each "UniLine" bioprosthesis is subject to mandatory preclinical hydrodynamic assessment in accordance with the National Standards of the Russian Federation (GOST 26997-2003 and GOST 52999-2008). The "UniLine" atrioventricular biological prosthesis is manufactured in standard sizes 26, 28, 30 and 32, the "UniLine" aortic biological prosthesis is manufactured in standard sizes 21, 23, 25.
Treating aortic or mitral valve disease using the "UniLine" biological prosthesis is expected to improve survival rates. Supposedly, in vivo the "UniLine" biological prosthesis will show optimal hemodynamic characteristics and high resistance to structural valve degeneration and infectious damage, thus lowering the risk of dysfunction. Moreover, the risk of repeated intervention due to dysfunction of the "UniLine" bioprosthesis should not exceed the risk of the primary implantation. Supposedly, in the case of dysfunction of "UniLine" bioprosthesis it would be possible to perform repeated replacement using valve-in-valve technique.
The aim of the study is to assess the effectiveness, safety, durability of the "UniLine" epoxy-treated prosthesis and the long-term outcome of the treatment of isolated mitral and aortic valve diseases using this prosthesis.
In accordance with the objectives and hypothesis, the following data will be analyzed: actuarial and linear survival rates (general and cardiac), non-lethal prosthesis-associated complications, prosthetic dysfunction and repeated interventions.
Moreover, in vivo hemodynamic parameters of the prosthesis will be assessed: the area of the effective opening surface, peak and mean gradient of pressure and blood flow velocity.
The study will be conducted at the Research Institute of Complex Issues of Cardiovascular Diseases. Study protocol received sponsorship approval and approval by Ethics Committee of the Research Institute and Research Coordinating Committee. The study will enroll 2000 patients who underwent isolated mitral or aortic valve replacement; transthoracic echocardiography will be conducted in all patients available for in-person visit.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Diseases of Mitral and Aortic Valves
Rheumatic Disorders of Mitral and Aortic Valves
Other Congenital Malformations of Aortic and Mitral Valves
Valvular Heart Disease (Aortic and Mitral Valves)
Mitral Valve Insufficiency and Aortic Valve Insufficiency
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients of both sexes aged 18 years and older who underwent isolated mitral or aortic valve replacement using the "UniLine" bioprosthesis
* No prior heart valve replacement
* No prior heart valve replacement
Exclusion Criteria
* The presence of a mechanical or biological prosthesis in another position
* Prior valve repair
* Aortic aneurysm repair (ascending aorta)
* Resection of a left ventricular aneurysm
* Patients with active cancer and patients with history of cancer
* Prior valve repair
* Aortic aneurysm repair (ascending aorta)
* Resection of a left ventricular aneurysm
* Patients with active cancer and patients with history of cancer
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CT Medical Limited Liability Company
UNKNOWN
Sponsor Role
collaborator
Research Institute for Complex Problems of Cardiovascular Diseases, Russia
OTHER
Sponsor Role
collaborator
Closed Joint-Stock Company NeoCor
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexander Bogachev-Prokofiev, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
National Medical Research Center named after Academician E.N. Meshalkin
Alexey Evtushenko, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Research Institute for Complex Issues of Cardiovascular Diseases
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Federal State Budgetary Scientific Institution "Research Institute for Complex Issues of Cardiovascilar Diseases"
Kemerovo, , Russia
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Russia
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UL RF - 01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement
NCT01531374
COMPLETED
NA
PROVE ACURATE neo2™ - Post Market Safety and Performance Surveillance in Aortic Stenosis
NCT05539573
ACTIVE_NOT_RECRUITING
Comparative Analysis of Stented Biological Prosthesis Versus Aortic Allograft in Patients With Degenerative Aortic Valve Disease
NCT07210541
COMPLETED
Immediate Suboptimal Result of Mitral Valve Repair: Late Implications in a Matched Cohort Study
NCT05836480
COMPLETED
Outcome of Preserved Mitral Valve Apparatus During Mitral Valve Replacement
NCT05438433
COMPLETED
NA
Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis
NCT04333875
COMPLETED
Safety and Efficacy of the GeminiOne Transcatheter Valve Edge-to-Edge Repair System in Patients With Moderate-severe or Severe Degenerative Mitral Regurgitation
NCT05655897
RECRUITING
NA
Treatment of Concomitant Mitral Regurgitation by Mitral Valve Clipping in Patients With Successful Transcatheter Aortic Valve Implantation.
NCT04009434
UNKNOWN
NA
Clinical Efficacy and Long-term Outcomes of ALLOgraft Versus Stented Biological Prosthesis for Primary TRIcuspid Valve Disease (ALLOTRI)
NCT06591000
RECRUITING
Mitral Valve in Hypertrophic Cardiomyopathy
NCT03877731
COMPLETED
NA
EASE MITRAL Expertise-based Assessment Study on Clinical Efficacy of Profile 3D in MITRAL Valve Annuloplasty
NCT01112566
COMPLETED
Assessment of Sustained Systolic-to-diastolic Flexibility of the Mitral Valve Annulus With the Sorin MEMO 3D Mitral Anuloplasty Ring
NCT01987635
COMPLETED
NA
accuRate Evaluation of Benefit With Optimal Medical Treatment With or Without Transcatheter Valve Repair of PARADOXical Low Flow Low Gradient Aortic Stenosis
NCT03863132
ACTIVE_NOT_RECRUITING
NA
Post-market Clinical Monitoring of the Safety and Efficacy of the Aortic Valve Bioprothesis
NCT05998694
RECRUITING
Are the Results of Minimally Invasive Mitral Valve Repair Still Satisfactory When Looked at Very Long-term?
NCT05836558
COMPLETED
Cerebrovascular EveNts in Patients Undergoing TranscathetER Aortic Valve Implantation With Balloon-expandable Valves Versus Self-expandable Valves.
NCT03588247
COMPLETED
Mechanisms of Excess Risk in Aortic Stenosis
NCT04627987
RECRUITING
Safety and Efficacy Study of the Sorin 3D Annuloplasty Ring For Mitral Repair
NCT00567853
COMPLETED
PHASE3
Prospective Russian Evaluation of Lp(a) Role in cardiovascUlar DiseasE
NCT02515747
COMPLETED
NA
The JenaValve ALIGN-AR LVAD Registry
NCT06594705
RECRUITING
NA
Early Versus Deferred Aortic Valve Replacement in Patients With Moderate Aortic Stenosis and Mitral Regurgitation
NCT05310461
RECRUITING
NA
RanDOmized stUdy Comparing Both Latest Generation Self-Expanding Valves and a Minimalist approaCH vs. Standard Of Care In transCathEter Aortic Valve Implantation
NCT05036018
ACTIVE_NOT_RECRUITING
NA
Edge-to-edge Mitral Valve Repair in the Surgical Treatment for Hypertrophic Cardiomyopathy
NCT04470102
UNKNOWN
NA
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).
NCT01586910
ACTIVE_NOT_RECRUITING
NA
The China Mviv Registry
NCT05925335
UNKNOWN
NA